Healthcare Industry Growth
Healthcare Companies Report Durable Growth Driven by Recurring Revenue and Specialty Services
Anonymous
Key Points
1
Veradigm’s payer business serves 84 clients and is expanding beyond risk analytics into provider-network management and in-workflow care-gap closure, including alternative network strategies for practices using non-Epic electronic medical records.
2
At Stevanato Group, high-value products generate gross margins of roughly 40% to 70%, far above bulk products. New facilities in Fishers and Latina are still ramping, with full efficiency and associated margin benefits expected by 2028.
3
STERIS has transformed its revenue mix over the past decade from about 80% capital equipment to 80% recurring revenue, supported by chemistries, service contracts and life sciences consumables.
4
Cencora said Walgreens remains a key strategic partner, while its relationship with Express Scripts and CuraScript remains stable; the company characterized generic and biosimilar insourcing by those partners as standard industry practice with minimal profit impact.
5
Veracyte’s planned UroAmp launch is expected in late 2028 and targets an estimated $400 million market for non-muscle-invasive bladder cancer, with potential expansion into other urologic diseases.
Healthcare companies are finding solid ground despite economic headwinds. At the Morgan Stanley Global Healthcare Conference, industry leaders reported durable demand driven by recurring revenue, specialty services, and AI-powered solutions. GuruFocus noted that companies are shifting away from one-time sales toward sticky, repeat business models that weather customer financial pressure.
Five major players revealed their playbooks. Veradigm is hunting untapped revenue-cycle services among independent practices. Stevanato Group is riding a wave of biologics and GLP-1 therapy demand. STERIS is locking in recurring revenue. Cencora is banking on specialty pharma distribution. And Veracyte is expanding its cancer-diagnostics arsenal through acquisition.
Veradigm Expands Beyond Risk Analytics
Veradigm's payer business now serves 84 clients and is shifting focus from pure risk analytics. SeekingAlpha reported the company is moving into provider-network management and in-workflow care-gap closure. The firm is also building alternative network strategies for practices stuck on non-Epic electronic medical records, capturing revenue from practices that lack Veradigm's native platform.
The Health Network Architecture data platform underpins this expansion. AI and workflow automation are the engines. Veradigm is targeting a massive underpenetrated market among independent practices that currently lack efficient revenue-cycle tools.
Stevanato's High-Margin Biologics Boom
Stevanato Group is reaping rewards from the boom in biologics, GLP-1 therapies, and sophisticated drug-delivery products. According to SeekingAlpha, high-value products carry gross margins of 40% to 70%—far above bulk products. New manufacturing facilities in Fishers, Indiana and Latina, Italy are still ramping up operations.
Full efficiency and margin benefits from these new plants are expected by 2028. The shift toward premium therapeutics—particularly injectable weight-loss drugs—should power growth through 2028 and beyond, the company indicated.
STERIS Transforms Into a Recurring Revenue Engine
STERIS has completed a dramatic portfolio overhaul over the past decade. ThBusinessTimes noted the company flipped its revenue mix from 80% capital equipment to 80% recurring revenue. Chemistries, service contracts, and life sciences consumables now drive the bulk of sales.
The company is seeing positive procedure volumes and strong demand for sterile processing and maintenance services. Market-share gains and sticky service contracts are building a more resilient, predictable business.
Cencora and Veracyte Chase Growth Through Niche Dominance
Cencora is betting on specialty pharmaceutical distribution and oncology-focused physician platforms to carry growth through 2027. SeekingAlpha reported the company views Walgreens as a key strategic partner and said its relationships with Express Scripts and CuraScript remain stable. Generic and biosimilar insourcing by those partners is standard industry practice with minimal profit impact, Cencora argued.
Veracyte is broadening its cancer-diagnostics footprint through the Convergent Genomics acquisition. The company expects continued adoption of Decipher, Afirma, and Prosigna tests as clinical evidence grows and physician awareness expands. A planned UroAmp launch in late 2028 targets a $400 million market for non-muscle-invasive bladder cancer, with potential expansion into other urologic diseases.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
11
Articles
34
Reach
45
Topics
A
AnonymousAuthor
